SEOM Clinical Guideline for the treatment of pancreatic cancer (2016)

R. Vera ^[1] ; E. Dotor ^[5] ; J. Feliu ^[2] ; E. González ^[3] ; B. Laquente ^[6] ; T. Macarulla ^[7] ; E. Martínez ^[4] ; J. Maurel ^[8] ; M. Salgado ^[9] ; J. L. Manzano ^[10]
1. [1] Gobierno de Navarra
  
  Gobierno de Navarra
  
  Pamplona, España
2. [2] Hospital Universitario La Paz
  
  Hospital Universitario La Paz
  
  Madrid, España
3. [3] Hospital Universitario Virgen de las Nieves
  
  Hospital Universitario Virgen de las Nieves
  
  Granada, España
4. [4] Hospital Universitario Marqués de Valdecilla
  
  Hospital Universitario Marqués de Valdecilla
  
  Santander, España
5. [5] Consorcio Sanitario de Terrassa, España
6. [6] ICO-Hospitalet de LLobregat, España
7. [7] Hospital Vall`Hebron, España
8. [8] Hospital Clínic i Provincial de Barcelona, España
9. [9] Complexo Hospitalario de Orense, España
10. [10] ICO-Badalona, España
Mostrar afiliaciones +
Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 18, Nº. 12 (December 2016), 2016, págs. 1172-1178
Idioma: inglés
Texto completo no disponible (Saber más ...)

Resumen
- Pancreatic cancer remains an aggressive disease with a 5 year survival rate of 5%. Only 15% of patients with pancreatic cancer are eligible for radical surgery. Evidence suggests a benefit on survival with adjuvant chemotherapy (gemcitabine o fluourouracil) after R1/R0 resection. Adjuvant chemoradiotherapy is also a valid option in patients with positive margins. Borderline resectable pancreatic cancer is defined as the involvement of the mesenteric vasculature with a limited extension. These tumors are technically resectable, but with a high risk of positive margins. Neoadjuvant treatment represents the best option for achieving an R0 resection. In advanced disease, two new chemotherapy treatment schemes (Folfirinox or Gemcitabine plus nab-paclitaxel) have showed improvements in overall survival compared with gemcitabine alone. Progress in pancreatic cancer treatment will require a better knowledge of the molecular biology of this disease, focusing on personalized cancer therapies in the near future.